Clinical Therapeutics/New Technology-Oral Agents

Clinical Therapeutics/New Technology-Oral Agents

You have access
The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes
Klara R. Klein, Jennifer L.R. Freeman, Imogene Dunn, Chris Dvergsten, M. Sue Kirkman, John B. Buse, Carmen Valcarce, on behalf of the SimpliciT1 research group

Diabetes Care Feb 2021, dc202684; DOI: 10.2337/dc20-2684
You have access
SGLT2 Inhibition Does Not Affect Myocardial Fatty Acid Oxidation or Uptake, but Reduces Myocardial Glucose Uptake and Blood Flow in Individuals With Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Crossover Trial
Katrine M. Lauritsen, Bent R.R. Nielsen, Lars P. Tolbod, Mogens Johannsen, Jakob Hansen, Troels K. Hansen, Henrik Wiggers, Niels Møller, Lars C. Gormsen, Esben Søndergaard

Diabetes Mar 2021, 70 (3) 800-808; DOI: 10.2337/db20-0921
Open Access
Response to Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128–2136
Roselle A. Herring, Fariba Shojaee-Moradie, Robert Garesse, Mary Stevenage, Nicola Jackson, Barbara A. Fielding, Agampodi Mendis, Sigurd Johnsen, A. Margot Umpleby, Melanie Davies, David L. Russell-Jones

Diabetes Care Mar 2021, 44 (3) e61; DOI: 10.2337/dci20-0072
Open Access
Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128–2136
Geremia B. Bolli, Francesca Porcellati, Paola Lucidi, Carmine G. Fanelli

Diabetes Care Mar 2021, 44 (3) e59-e60; DOI: 10.2337/dc20-2575
Open Access
DPP-4 Inhibitors and Respiratory Infection: A Systematic Review and Meta-analysis of the Cardiovascular Outcomes Trials
Guillaume Grenet, Samia Mekhaldi, Sabine Mainbourg, Marine Auffret, Catherine Cornu, Jean-Luc Cracowski, François Gueyffier, Jean-Christophe Lega, Michel Cucherat

Diabetes Care Mar 2021, 44 (3) e36-e37; DOI: 10.2337/dc20-2018
Open Access
Metformin Benefits: Another Example for Alternative Energy Substrate Mechanism?
Andrea Giaccari, Anna Solini, Simona Frontoni, Stefano Del Prato

Diabetes Care Mar 2021, 44 (3) 647-654; DOI: 10.2337/dc20-1964
You have access
Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial
Julie Dubourg, Pascale Fouqueray, Carole Thang, Jean-Marie Grouin, Kohjiro Ueki

Diabetes Care Feb 2021, dc200763; DOI: 10.2337/dc20-0763
Open Access
Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial
Rosalie A. Scholtes, Marcel H.A. Muskiet, Michiel J.B. van Baar, Anne C. Hesp, Peter J. Greasley, Cecilia Karlsson, Ann Hammarstedt, Niki Arya, Daniël H. van Raalte, Hiddo J.L. Heerspink

Diabetes Care Feb 2021, 44 (2) 440-447; DOI: 10.2337/dc20-2604
You have access
Effects of Vitamin C Supplementation on Glycemic Control and Cardiovascular Risk Factors in People With Type 2 Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis of Randomized Controlled Trials
Shaun A. Mason, Michelle A. Keske, Glenn D. Wadley

Diabetes Care Feb 2021, 44 (2) 618-630; DOI: 10.2337/dc20-1893
You have access
Association of Baseline Characteristics With Insulin Sensitivity and β-Cell Function in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study Cohort
Neda Rasouli, Naji Younes, Kristina M. Utzschneider, Silvio E. Inzucchi, Ashok Balasubramanyam, Andrea L. Cherrington, Faramarz Ismail-Beigi, Robert M. Cohen, Darin E. Olson, Ralph A. DeFronzo, William H. Herman, John M. Lachin, Steven E. Kahn, the GRADE Research Group

Diabetes Care Feb 2021, 44 (2) 340-349; DOI: 10.2337/dc20-1787

Main menu

User menu

Search

Clinical Therapeutics/New Technology-Oral Agents

Pages

Navigate

More Information

Other ADA Resources